Moleculera Biosciences

Moleculera Biosciences operates in the healthcare sector, focusing on precision testing to improve patient care. The company specializes in developing and providing advanced antibody tests that help identify immune-mediated responses potentially causing neurological and psychiatric symptoms. These tests are particularly relevant for conditions such as autism, chronic fatigue, depression, epilepsy, and motor and vocal tics. By targeting healthcare providers, Moleculera Biosciences serves a niche market of patients with treatment-resistant symptoms, offering a diagnostic tool that can lead to more effective treatment plans. The business model revolves around selling these specialized tests to medical professionals and healthcare institutions, generating revenue through test sales and strategic alliances. The company's approach is grounded in leveraging real-world data to transform patient care, aiming to uncover underlying autoimmune processes that traditional psychiatric diagnoses might overlook. Keywords: antibody tests, immune response, neurological, psychiatric, precision testing, healthcare, autoimmune, diagnostics, patient care, treatment-resistant.